Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБНУ «Научный центр психического здоровья», Москва, Россия 2ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия 3Научно-исследовательский институт психического здоровья «Томский научный исследовательский медицинский центр Российской академии наук», Томск, Россия sertraline@list.ru
Список исп. литературыСкрыть список 1.Jean C. Yi, PhD and Karen L. Syrjala Anxiety and Depression in Cancer Survivors Med Clin North Am. 2017; 101 (6): 1099–1113. doi: 10.1016/j.mcna.2017.06.005 2.Пономарева Л.А., Сухарева Е.А., Егорова А.Г., Сомов А.Н. Опыт реализации мер по снижению смертности от рака молочной железы. Онкология. Журнал им. П.А. Герцена. 2015; 4(6): 42–47. doi:10.17116/onkolog20154642-47 [Ponomareva L.A., Sukhareva E.A., Egorova A.G., Somov A.N.] Experience in implementing measures to reduce mortality from breast cancer. Oncology. Journal P.A. Herzen. 2015; 4 (6): 42–47. doi:10.17116/onkolog20154642-47 3.Chad Friedman E, Coleman S, Trarger LN et al. Psychological distress associated with cancer screening: A systematic review. Canser. 2017; 123 (20): 3882–3894. doi: 10.1002/cncr.30904. Epub 2017 Aug 22. 4.Шушпанова О. В. Психические нарушения у больных раком молочной железы: дифференцированный подход к изучению нозогений Журнал неврологии и психиатрии им. С.С. Корсакова. 2017; 117 (8): 18–26. doi: 10.17116/jnevro20171178118-26 [Shushpanova O.V.] Mental disorders in patients with breast cancer: a differentiated approach to the study of nosogeny. Journal of Neurology and Psychiatry. S.S. Korsakova. 2017; 117 (8): 18–26. doi: 10.17116/jnevro 20171178118-26 5.Нелюбина Л.А., Лактионов К.П. Причины заболевания раком молочной железы и возможности его профилактики. Вестник РОНЦ им.Н.Н.Блохина РАМН. 2013; 24 (92): 3–10. [Nelyubina L.A., Laktionov K.P.] Causes of breast cancer and the possibility of its prevention. Bulletin of the Russian Research Center N.N. Blokhina RAMS. 2013; 24 (92): 3–10. 6.Состояние онкологической помощи населению России в 2016 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России, 2017; 236 с. The status of cancer care for the population of Russia in 2016. Ed. HELL. Kaprina, V.V. Starinsky, G.V. Petrova. M.: Moscow P.A. Herzen – a branch of the FSBI "NIIRTS" of the Ministry of Health of Russia, 2017; 236 p. 7.Галиуллина С.Д. Нервно-психические нарушения у больных раком молочной железы: Автореферат дис. канд. мед. наук, Уфа, 2000; 23 с. [Galiullina, S.D.] Neuropsychiatric disorders in patients with breast cancer: Abstract dis. Cand. Med.. Sciences, Ufa, 2000; 23 p. 8.Терентьев И. Г., Алясова А.В., Трошин В.Д. Нервно-психические расстройства у больных раком молочной железы .Нижний Новгород.: Изд-во Нижегородской государственной медицинской академии, 2004; 264 с. [Terentyev I.G., Alyasova A.V., Troshin V.D. ] Neuropsychiatric disorders in patients with breast cancer. Nizhny Novgorod .: Publishing house of the Nizhny Novgorod State Medical Academy, 2004; 264 p. 9.Bringmann H, Singer S, HЪckel M. [et al ]. Longitudinal analysis of psychiatric morbidity in cancer patients. Onkologie. 2008; 31 (6): 343–4. doi: 10.1159/000132166. 10.Самушия М. А., Зубова И. В. Нозогении (психогенные реакции) при раке молочной железы. Психические расстройства в общей медицине. 2009; 1: 24–29. [Samushia M. A., Zubova I. V.] Nosogeny (psychogenic reactions) in breast cancer. Mental disorders in general medicine. 2009; 1: 24–29. 11.Володин Б.Ю. психосоматические взаимоотношения у онкологических больных. Паллиативная медицина и реабилитация. 2007; 3: 51–54. [Volodin B.Yu.] psychosomatic relationships in cancer patients. Palliative medicine and rehabilitation. 2007; 3: 51–54. 12.Тарабрина Н.В., Ворона О.А., Курчакова М.С. [и др.]. Онкопсихология: посттравматический стресс у больных раком молочной железы ISBN: 978-5-9270-0184-2 175 с (моногр) под ред Клочкова И.С., Институт психологии РАН, 2010. [Tarabrina N.V., Vorona O.A., Kurchakova M.S. [et al] Oncopsychology: post-traumatic stress in patients with breast cancer ISBN: 978-5-9270-0184-2 175 s (monograph) edited by I. Klochkova, Institute of Psychology RAS, 2010 13.Kang J, Sung N, Park S et al. The epidemiology of psychiatric disorders among women with breast cancer in South Korea: analysis of national registry data. Psychooncology. 2014; 23 (1): 35–9. doi: 10.1002/pon.3369. 14.Butow P, Kelly S, Thewes B et al. Attentional bias and metacognitions in cancer survivors with high fear of cancer recurrence. Psychooncology. 2015; 24 (4): 416–23. doi: 10.1002/pon.3659. 15.Sanjida S, Janda M, Kissane D et al. A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients. Psychooncology. 2016; 25 (9): 1002–1016. doi: 10.1002/pon.4048. 16.Ramaswami R, Villarreal MD, Pitta DM et al. Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2015; 152 (2): 231–7. doi: 10.1007/s10549-015-3465-5 17.L’Espérance S, Frenette S, Dionne A, Dionne JY. Comité de l’évolution des pratiques en oncologie (CEPO). Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer. 2013; 21:1461–1474. doi: 10.1007/s00520-013-1732-8. 18.Wiśniewska I, Jochymek B, Lenart-Lipińska M et al. Chabowskicorresponding M. The pharmacological and hormonal therapy of hot flushes in breast cancer survivors. Breast Cancer. 2016; 23: 178–182. doi: 10.1007/s12282-015-0655-2 19.Kimmick GG, Lovato J, McQuellon R et al. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J. 2006; 12 (2): 114–22. doi: 10.1111/j.1075-122X. 2006.00218.x 20.Biglia N, Bounous VE, Susini T et al. Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors. Eur J Cancer Care (Engl). 2018; 27 (1). doi: 10.1111/ecc.12484. 21.Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain. 1996; 64 (2): 293–302. doi: 10.1016/0304-3959(95)00138-7 22.Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res. Treat. 2001; 70 (1): 1–10. doi: 10.1023/a:1012518831494 23.Roscoe J., Morrow GR, Hickok JT et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat. 2005 Feb; 89 (3): 243–9. doi: 10.1007/s10549-004-2175-1 24.Möslinger-Gehmayr R, Zaninelli R, Contu A et al. A double-blind comparative study of the effectiveness and tolerance of paroxetine and amitriptyline in treatment of breast cancer patients with clinically assessed depression Zentralbl Gynakol. 2000; 122 (4): 195–202. 25.Grassi L, Nanni MG, Rodin G et al. The use of antidepressants in oncology: a review and practical tips for oncologists. Ann Oncol. 2018; 29 (1): 101–111. doi: 10.1093/annonc/mdx526. 26.Medical Services Commission. Palliative care for the patient with incurable cancer or advanced disease. Part 2: Depression. Victoria (BC): British Columbia Medical Services Commission. 2011 [cited 2013 Nov 3]. Available from: http://www.bcguidelines.ca/pdf/palliative2_ depression.pdf 27.Fulcher CD, Badger T, Gunter AK et al. Putting evidence into practice: interventions for depression. Clin J Oncol Nurs 2008; 12 (1): 131–40. doi: 10.1188/08.CJON.131-140. 28.Caraci F, Crupi R, Drago F et al. Metabolic Drug Interactions Between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract. Current Drug Metabolism. 2011; 12 (6): 570–577. doi: 10.2174/138920011795713706 29.Irarrázaval OME. .Antagonism of tamoxifen and antidepressants among women with breast cancer. Rev Med Chil. 2011; 139(1): 89-99. doi: /S0034-98872011000100013. 30.Wedret JJ, Tu TG, Paul D et al. Interactions between antidepressants, sleep aids and selected breast cancer therapy. Ment Illn. 2019; 11(1): 8115. doi: 10.4081/mi.2019.8115. 31.Torta R, Siri I, Caldera P. Sertraline effectiveness and safety in depressed oncological patients. Support Care Cancer. 2008; 16 (1): 83–91. doi: 10.1007/s00520-007-0269-0. 32.Schillani G, Capozzo MA, Era D et al. Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care: report of 18 cases. Tumori. 2011; 97 (3): 358–361. doi: 10.1700/912.10034. 33.Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005; 62:190-198. DOI: 10.1001/archpsyc.62.2.190 34.Grassi L, Caruso R, Hammelef K et al. Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review. Int Rev Psychiatry. 2014; 26(1): 44–62. doi: 10.3109/09540261.2013.842542 35.Navari RM, Brenner MC, Wilson MN. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat. 2008; 112 (1): 197–201. doi: 10.1007/s10549-007-9841-z. 36.Frampton JE, Plosker GL. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs. 2007; 21: 581-609. doi: 10.2165/00023210-200721070-00004 37.Torta R, Leombruni P, Borio R, Castelli L. Duloxetine for the treatment of mood disorder in cancer patients: a 12-week case-control clinical trial. Hum Psychopharmacol. 2011; 26: 291–299. doi: 10.1002/hup.1202 38.Spiegel D, Riba MB. Managing anxiety and depression during treatment. Breast J. 2015; 21(1): 97–103. doi: 10.1111/tbj.12355 39.Rustad JK, David D, Currier MB. Cancer and post-traumatic stress disorder: diagnosis, pathogenesis and treatment considerations. Pall Supp Care. 2012; 10 (3): 213–223. doi: 10.1017/S1478951511000897 40.Baldwin D.S., Anderson I.M., Nutt D.J. [et al]. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014; 28(5): 403–439. doi: 10.1177/0269881114525674 41.Ersoy MA, Noyan AM, Elbi H. An Open-Label Long-Term Naturalistic Study of Mirtazapine Treatment for Depression in Cancer Patients. Clin Drug Investig. 2008; 28 (2): 113–20. doi: 10.2165/00044011-200828020-00005. 42.Carvalho AF, Hyphantis T, Sales PM et al. Major depressive disorder in breast cancer: a critical systematic review of pharmacological and psychotherapeutic clinical trials. Cancer Treat Rev. 2014; 40 (3): 349–55. doi: 10.1016/j.ctrv.2013.09.009/